MDx Health Signs Exclusive Canadian Agreement
You may also be interested in...
MDx Health has named a new CEO to lead its commercial growth following a disappointing set of results in 2018.
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.